BRCA1 and cancer: Similarly, among the 5,792 individuals within the nonindication-based cohort who had comprehensive multigene panel genetic testing, 12 (0.2%) had an AJ BRCA1/2 founder mutation, whereas 195 (3.4%) had a PLPV in any actionable cancer risk gene.